Stay updated with breaking news from Pharmaceutical Intelligence. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
DISC-0974 is under clinical development by Disc Medicine and currently in Phase II for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis).
Bitopertin is under clinical development by Disc Medicine and currently in Phase II for Anemia.
NPT-189 is under clinical development by Proclara Biosciences and currently in Phase I for Primary Systemic Amyloidosis.
FOG-001 is under clinical development by Fog Pharmaceuticals and currently in Phase II for Non-Small Cell Lung Cancer.
ABBV-101 is under clinical development by AbbVie and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia (CLL).